Top Medical Stocks To Follow Now – November 10th

Hims & Hers Health, Stryker, Danaher, Gilead Sciences, Boston Scientific, McKesson, and Medtronic are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of companies involved in healthcare, such as pharmaceutical and biotechnology firms, medical-device makers, hospitals, and healthcare suppliers. For investors, the term describes a broad stock-market category whose performance can be shaped by factors such as medical research, regulation, and demand for healthcare. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Shares of HIMS traded down $4.38 during mid-day trading on Tuesday, reaching $18.55. The stock had a trading volume of 39,270,967 shares, compared to its average volume of 22,309,057. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of -29.36 and a beta of 2.53. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $41.28. The business has a fifty day moving average of $28.31 and a 200 day moving average of $26.91. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Stryker (SYK)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Stryker stock traded down $3.88 during mid-day trading on Tuesday, hitting $321.85. The stock had a trading volume of 1,138,320 shares, compared to its average volume of 2,507,694. The firm’s 50 day moving average is $292.26 and its 200 day moving average is $323.41. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Stryker has a one year low of $267.00 and a one year high of $389.33. The firm has a market capitalization of $122.53 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.33 and a beta of 0.78.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

NYSE DHR traded down $0.32 on Tuesday, reaching $234.80. The company had a trading volume of 1,312,493 shares, compared to its average volume of 4,437,830. The stock has a market capitalization of $165.19 billion, a PE ratio of 38.52, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The firm’s 50 day moving average price is $220.65 and its 200 day moving average price is $201.57.

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of Gilead Sciences stock traded up $0.27 during trading on Tuesday, reaching $169.59. 1,233,047 shares of the stock traded hands, compared to its average volume of 6,818,232. The company has a market capitalization of $210.35 billion, a price-to-earnings ratio of -53.68 and a beta of 0.35. The business has a fifty day simple moving average of $153.51 and a two-hundred day simple moving average of $141.14. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences has a 52-week low of $116.88 and a 52-week high of $176.58.

Boston Scientific (BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Boston Scientific stock traded down $0.03 during midday trading on Tuesday, reaching $43.99. 4,573,460 shares of the stock traded hands, compared to its average volume of 18,767,520. The stock’s fifty day moving average is $44.26 and its 200-day moving average is $55.46. Boston Scientific has a 12 month low of $39.57 and a 12 month high of $105.65. The stock has a market cap of $63.76 billion, a P/E ratio of 18.66, a PEG ratio of 1.36 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.36 and a debt-to-equity ratio of 0.42.

McKesson (MCK)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

McKesson stock traded up $14.29 during mid-day trading on Tuesday, reaching $1,073.66. 180,308 shares of the company’s stock traded hands, compared to its average volume of 914,138. The company has a market cap of $125.18 billion, a price-to-earnings ratio of 27.62, a PEG ratio of 2.13 and a beta of 0.27. The stock has a 50 day moving average of $941.40 and a two-hundred day moving average of $869.30. McKesson has a 12-month low of $723.68 and a 12-month high of $1,121.50.

Medtronic (MDT)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Shares of Medtronic stock traded down $1.34 during trading on Tuesday, hitting $101.45. The stock had a trading volume of 1,804,267 shares, compared to its average volume of 11,249,218. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The firm’s fifty day simple moving average is $92.93 and its 200-day simple moving average is $88.46. The stock has a market cap of $129.76 billion, a PE ratio of 25.02, a PEG ratio of 2.46 and a beta of 0.56. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.